CTEV
Claritev Corp
$
69.250
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
73.680
Open
70.000
VWAP
68.67
Vol
196.90K
Mkt Cap
1.14B
Low
60.010
Amount
13.52M
EV/EBITDA(TTM)
10.89
Total Shares
16.51M
EV
5.73B
EV/OCF(TTM)
325.28
P/S(TTM)
1.19
Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.
Show More
2 Analyst Rating
Wall Street analysts forecast CTEV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTEV is 80.00 USD with a low forecast of 74.00 USD and a high forecast of 86.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 69.250
Low
74.00
Averages
80.00
High
86.00
Current: 69.250
Low
74.00
Averages
80.00
High
86.00
Citi
Neutral -> Buy
upgrade
$55 -> $74
2025-10-22
Reason
Citi
Price Target
$55 -> $74
2025-10-22
upgrade
Neutral -> Buy
Reason
Citi yesterday morning upgraded Claritev to Buy from Neutral with a price target of $74, up from $55. The firm has confidence in the company's plan to accelerate growth. It believes Claritev will get back to mid-single-digit growth in 2026 while keeping "best-in-class" margins, the analyst told investors in a research note. This report corrects the price target on the shares.
Citi
Neutral -> Buy
upgrade
$55
2025-10-21
Reason
Citi
Price Target
$55
2025-10-21
upgrade
Neutral -> Buy
Reason
Citi upgraded Claritev to Buy from Neutral with an unchanged price target of $55 ahead of the Q3 report. The firm has confidence in the company's plan to accelerate growth. It believes Claritev will get back to mid-single-digit growth in 2026 while keeping "best-in-class" margins, the analyst tells investors in a research note.
Piper Sandler
Overweight
maintain
$44 -> $86
2025-08-15
Reason
Piper Sandler
Price Target
$44 -> $86
2025-08-15
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Claritev to $86 from $44 and keeps an Overweight rating on the shares. The firm hopes Q2's beat and raise marked the beginning of a new operating regime at Claritev. From here, Piper thinks multiple expansion is limited by the company's risk profile - specifically antitrust risk and customer concentration risk.
Piper Sandler
Jessica Tassan
Neutral -> Overweight
upgrade
$19 -> $44
2025-05-29
Reason
Piper Sandler
Jessica Tassan
Price Target
$19 -> $44
2025-05-29
upgrade
Neutral -> Overweight
Reason
Piper Sandler
Jessica Tassan
Neutral
to
Overweight
upgrade
$19 -> $44
2025-05-28
Reason
Piper Sandler
Jessica Tassan
Price Target
$19 -> $44
2025-05-28
upgrade
Neutral
to
Overweight
Reason
Piper Sandler analyst Jessica Tassan upgraded Claritev to Overweight from Neutral with a price target of $44, up from $19.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Claritev Corp (CTEV.N) is -5.87, compared to its 5-year average forward P/E of -3.47. For a more detailed relative valuation and DCF analysis to assess Claritev Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.47
Current PE
-5.87
Overvalued PE
-2.17
Undervalued PE
-4.77
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Overvalued
5Y Average EV/EBITDA
8.90
Current EV/EBITDA
9.65
Overvalued EV/EBITDA
9.33
Undervalued EV/EBITDA
8.47
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
4.69
Current PS
69.25
Overvalued PS
20.41
Undervalued PS
-11.03
Financials
Annual
Quarterly
FY2025Q3
YoY :
+6.71%
245.96M
Total Revenue
FY2025Q3
YoY :
-58.49%
10.07M
Operating Profit
FY2025Q3
YoY :
-82.18%
-69.75M
Net Income after Tax
FY2025Q3
YoY :
-82.56%
-4.23
EPS - Diluted
FY2025Q3
YoY :
-139.73%
-16.35M
Free Cash Flow
FY2025Q3
YoY :
+10.33%
29.26
Gross Profit Margin - %
FY2025Q3
YoY :
-324.48%
-11.83
FCF Margin - %
FY2025Q3
YoY :
-100.00%
N/A
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 573.17% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
969.4K
Volume
Months
0-12
1
144.0K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CTEV News & Events
Events Timeline
2025-11-07 (ET)
2025-11-07
06:23:33
Claritev Adjusts FY25 Revenue Forecast to 2.8%-3.2%, Up from Flat to 2%
2025-11-07
06:21:49
Claritev Announces Q3 EPS of $4.23 Compared to ($24.25) in the Previous Year
2025-10-27 (ET)
2025-10-27
17:02:18
Claritev reveals strategic investment in Klaim
Sign Up For More Events
Sign Up For More Events
News
9.5
11-07NASDAQ.COMPinnedClaritev Corporation Reports Reduced Losses in Q3
7.5
10-28Yahoo FinanceClaritev Invests in Klaim to Improve Provider Payment Services in the US and MENA Regions
7.5
10-08NewsfilterClaritev and iO Health Establish Strategic Partnership to Enhance AI-Driven Revenue Cycle Management in the MENA Region
Sign Up For More News
People Also Watch
TSLA
Tesla Inc
429.520
USD
-3.68%
NVDA
NVIDIA Corp
188.150
USD
+0.04%
MSFT
Microsoft Corp
496.820
USD
-0.06%
AAPL
Apple Inc
268.470
USD
-0.48%
META
Meta Platforms Inc
621.710
USD
+0.45%
AVGO
Broadcom Inc
349.430
USD
-1.73%
ORCL
Oracle Corp
239.260
USD
-1.86%
WMT
Walmart Inc
102.590
USD
+0.89%
AMZN
Amazon.com Inc
244.410
USD
+0.56%
XOM
Exxon Mobil Corp
117.220
USD
+2.38%
FAQ
What is Claritev Corp (CTEV) stock price today?
The current price of CTEV is 69.25 USD — it has increased 11.77 % in the last trading day.
What is Claritev Corp (CTEV)'s business?
What is the price predicton of CTEV Stock?
What is Claritev Corp (CTEV)'s revenue for the last quarter?
What is Claritev Corp (CTEV)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Claritev Corp (CTEV)'s fundamentals?
How many employees does Claritev Corp (CTEV). have?